Nanjing Gaoke Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Nanjing Gaoke.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Real Estate Gewinnwachstum	40.2%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Earnings Troubles May Signal Larger Issues for Nanjing Gaoke (SHSE:600064) Shareholders

Nov 03

Improved Earnings Required Before Nanjing Gaoke Company Limited (SHSE:600064) Stock's 25% Jump Looks Justified

Oct 01

Is Nanjing Gaoke (SHSE:600064) Using Debt In A Risky Way?

Aug 27

Earnings Working Against Nanjing Gaoke Company Limited's (SHSE:600064) Share Price

Aug 01

We Think You Can Look Beyond Nanjing Gaoke's (SHSE:600064) Lackluster Earnings

May 03

Benign Growth For Nanjing Gaoke Company Limited (SHSE:600064) Underpins Its Share Price

Apr 18

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Nanjing Gaoke jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

SHSE:600064 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2024	2,011	1,728	-1,385	-1,361	N/A
6/30/2024	3,004	1,425	-2,497	-2,474	N/A
3/31/2024	3,808	1,445	-2,205	-2,181	N/A
12/31/2023	4,733	1,560	-2,198	-2,177	N/A
9/30/2023	6,772	2,182	-2,303	-2,289	N/A
6/30/2023	5,775	2,155	-2,173	-2,162	N/A
3/31/2023	5,262	2,375	-2,396	-2,392	N/A
12/31/2022	4,490	2,402	-1,874	-1,869	N/A
9/30/2022	2,691	2,286	-366	-359	N/A
6/30/2022	2,800	2,324	988	996	N/A
3/31/2022	3,405	2,467	1,138	1,147	N/A
12/31/2021	4,935	2,352	491	501	N/A
9/30/2021	4,706	2,160	-322	-312	N/A
6/30/2021	4,413	2,025	-1,561	-1,552	N/A
3/31/2021	4,140	1,979	-2,728	-2,720	N/A
12/31/2020	2,924	2,016	-2,184	-2,178	N/A
9/30/2020	4,119	2,190	-2,130	-2,125	N/A
6/30/2020	4,272	2,070	-638	-634	N/A
3/31/2020	3,357	1,529	774	778	N/A
12/31/2019	2,930	1,842	1,173	1,175	N/A
9/30/2019	2,053	1,626	2,269	2,286	N/A
6/30/2019	2,262	1,450	1,677	1,697	N/A
3/31/2019	2,890	1,676	1,038	1,057	N/A
12/31/2018	3,425	958	442	465	N/A
9/30/2018	4,321	1,201	-470	-448	N/A
6/30/2018	4,131	1,136	N/A	-268	N/A
3/31/2018	3,759	1,029	N/A	667	N/A
12/31/2017	3,626	946	N/A	184	N/A
9/30/2017	2,365	562	N/A	105	N/A
6/30/2017	2,630	676	N/A	1,124	N/A
3/31/2017	3,874	759	N/A	1,493	N/A
12/31/2016	5,221	927	N/A	2,108	N/A
9/30/2016	6,234	1,033	N/A	2,490	N/A
6/30/2016	6,340	1,094	N/A	1,680	N/A
3/31/2016	5,151	761	N/A	1,295	N/A
12/31/2015	3,882	848	N/A	1,719	N/A
9/30/2015	3,764	1,036	N/A	1,705	N/A
6/30/2015	3,293	862	N/A	1,747	N/A
3/31/2015	3,025	902	N/A	1,421	N/A
12/31/2014	3,286	610	N/A	1,268	N/A
9/30/2014	3,014	438	N/A	1,007	N/A
6/30/2014	3,279	456	N/A	704	N/A
3/31/2014	3,880	434	N/A	713	N/A
12/31/2013	3,529	430	N/A	910	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if 600064's forecast earnings growth is above the savings rate (2.9%).

Ertrag vs. Markt: Insufficient data to determine if 600064's earnings are forecast to grow faster than the CN market

Hohe Wachstumserträge: Insufficient data to determine if 600064's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if 600064's revenue is forecast to grow faster than the CN market.

Hohe Wachstumseinnahmen: Insufficient data to determine if 600064's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if 600064's Return on Equity is forecast to be high in 3 years time

Nanjing Gaoke Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to CN¥9.54

Price target decreased to CN¥9.54

Analysts increase EPS estimates to CN¥1.44

Price target raised to CN¥12.82

Recent updates

Earnings Troubles May Signal Larger Issues for Nanjing Gaoke (SHSE:600064) Shareholders

Third quarter 2024 earnings released: EPS: CN¥0.47 (vs CN¥0.30 in 3Q 2023)

Improved Earnings Required Before Nanjing Gaoke Company Limited (SHSE:600064) Stock's 25% Jump Looks Justified

Nanjing Gaoke Company Limited to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 15%

Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.30 in 2Q 2023)

Is Nanjing Gaoke (SHSE:600064) Using Debt In A Risky Way?

Earnings Working Against Nanjing Gaoke Company Limited's (SHSE:600064) Share Price

Dividend of CN¥0.28 announced

Nanjing Gaoke Company Limited to Report First Half, 2024 Results on Aug 30, 2024

We Think You Can Look Beyond Nanjing Gaoke's (SHSE:600064) Lackluster Earnings

Nanjing Gaoke Company Limited, Annual General Meeting, May 23, 2024

Full year 2023 earnings released: EPS: CN¥0.90 (vs CN¥1.39 in FY 2022)

Nanjing Gaoke Company Limited, Annual General Meeting, May 23, 2024

Benign Growth For Nanjing Gaoke Company Limited (SHSE:600064) Underpins Its Share Price

Nanjing Gaoke Company Limited to Report Q1, 2024 Results on Apr 27, 2024

Now 22% overvalued

Nanjing Gaoke Company Limited to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.43 in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.37 (vs CN¥0.39 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.30 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.51 in 2Q 2021)

Price target decreased to CN¥9.54

Less than half of directors are independent

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to CN¥9.54

Third quarter 2021 earnings released: EPS CN¥0.42 (vs CN¥0.31 in 3Q 2020)

njing Hanxin Pharmaceutical Technology Co., Ltd. intends to acquire 51% stake in Nanjing Cuccess Pharmaceutical Co., Ltd. from Nanjing Gaoke Company Limited (SHSE:600064) for approximately CNY 180 million.

Second quarter 2021 earnings released: EPS CN¥0.71 (vs CN¥0.68 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.48 in 1Q 2020)

New 90-day low: CN¥9.86

Third quarter earnings released

New 90-day low: CN¥10.13

First half earnings released

New 90-day high - CN¥12.06

Analysts increase EPS estimates to CN¥1.44

Price target raised to CN¥12.82

Nanjing Gaoke Company Limited to Report First Half, 2020 Results on Aug 31, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken